ONWARD Medical Posts Strong 2025 Results, Expands US Commercial Footprint
Event summary
- ONWARD Medical sold 117 ARC-EX Systems in 2025, achieving 25% US market penetration in specialized rehabilitation clinics.
- The company received FDA 510(k) clearance for home use of the ARC-EX System in November 2025.
- ONWARD raised EUR 50.8M in equity capital in October 2025, ending the year with EUR 68.1M in cash.
- The Empower BP global pivotal study for the ARC-IM System began in Q1 2026 with the first participant enrollment at Craig Hospital.
The big picture
ONWARD Medical's strong 2025 performance underscores the growing demand for its neurotechnology solutions in the spinal cord injury market. The company's ability to secure regulatory approvals and expand its commercial footprint positions it as a key player in the neurotechnology sector. The successful initiation of the Empower BP study further solidifies its leadership in developing innovative therapies for movement disabilities.
What we're watching
- Commercial Expansion
- The pace at which ONWARD can scale ARC-EX sales in Europe and other geographies will determine its ability to sustain revenue growth.
- Regulatory Milestones
- The success of the Empower BP study will be critical for the ARC-IM System's path to market approval and commercialization.
- Pipeline Advancements
- How quickly ONWARD can advance its ARC-BCI and Parkinson's disease programs will impact its long-term competitive positioning.
Related topics